ABBV-932 / AbbVie, Gedeon Richter - LARVOL DELTA

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder (clinicaltrials.gov) - P2 | N=315 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Trial completion • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: AbbVie

New P1 trial

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder (clinicaltrials.gov) - P2 | N=315 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • Bipolar Disorder • CNS Disorders • Depression • Psychiatry

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2024 ➔ May 2025 | Initiation date: May 2024 ➔ Aug 2024 | Trial primary completion date: Oct 2024 ➔ May 2025

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Bipolar Disorder • CNS Disorders • Depression • Psychiatry

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD) (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: AbbVie | N=64 ➔ 96

Enrollment change • Bipolar Disorder • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=104 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=104 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: AbbVie | Trial completion date: Feb 2024 ➔ Jun 2024 | Trial primary completion date: Feb 2024 ➔ Jun 2024

Adverse events • Trial completion date • Trial primary completion date • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Patients With Generalized Anxiety Disorder (GAD) and Patients With Schizophrenia (SCZ) (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: AbbVie | N=56 ➔ 88 | Trial completion date: Mar 2025 ➔ Nov 2024 | Trial primary completion date: Mar 2025 ➔ Nov 2024

Enrollment change • Trial completion date • Trial primary completion date • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: AbbVie | Trial completion date: Sep 2023 ➔ Feb 2024 | Trial primary completion date: Sep 2023 ➔ Feb 2024

Adverse events • Trial completion date • Trial primary completion date • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Study to Evaluate Adverse Events ABBV-932 and How Oral ABBV-932 Capsules Move Through the Body in Healthy Adults and Participants With Generalized Anxiety Disorder (GAD) (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

A Study to Evaluate Adverse Events ABBV-932 and How Oral ABBV-932 Capsules Move Through the Body in Healthy Adults and Participants With Generalized Anxiety Disorder (GAD) (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P1 trial • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants (clinicaltrials.gov) - P1 | N=84 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P1 trial • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry